Do you want to remove all your recent searches?

All recent searches will be deleted

AUVI-Q The Manufacturing Story

2 years ago32 views

multivu

MultiVu

Kaléo, a privately-held pharmaceutical company, today announced that it will reintroduce AUVI-Q® (epinephrine injection, USP) auto-injector to the U.S. market in the first half of 2017. AUVI-Q is a prescription medicine used to treat life-threatening allergic reactions, including anaphylaxis, in people who are at risk for or have a history of serious allergic reactions.

“Today’s news represents an important milestone for the life-threatening allergy community, which has suffered from a lack of epinephrine auto-injector options for far too long,” said Evan Edwards, Vice President of Product Development & Industrialization at kaléo. “As the inventors of AUVI-Q, my brother and I have dedicated our lives to researching and developing an innovative epinephrine auto-injector that would do for severe allergy sufferers what the AEDs did for cardiac arrest in the community; namely a product that could assist and guide even an untrained user through a life-threatening emergency.”
To view the multimedia release go to:

https://www.multivu.com/players/English/7940951-auvi-q-epinephrine-auto-injector-comeback

Report this video

Select an issue

Embed the video

AUVI-Q The Manufacturing Story
Autoplay
<iframe frameborder="0" width="480" height="270" src="//www.dailymotion.com/embed/video/x4z7a95" allowfullscreen allow="autoplay"></iframe>
Add the video to your site with the embed code above